<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K/A
(AMENDMENT NO. 1)
(Mark One)
[ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _____________ TO ______________
Commission file number: 0-21068
SIGHT RESOURCE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 04-3181524
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
67 SOUTH BEDFORD STREET, BURLINGTON, MA 01803
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 229-1100
Securities registered pursuant to Section 12(b) of the Exchange Act: NONE.
Securities registered pursuant to Section 12(g) of the Exchange Act:
Common Stock, $.01 par value per share
--------------------------------------
(Title of Class)
Redeemable Warrants, each exercisable for the purchase of one share of
Common Stock, $.01 par value per share, at $6.00
------------------------------------------------
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of the registrant's voting stock held by
non-affiliates of the registrant (without admitting that any person whose shares
are not included in such calculation is an affiliate) on March 17, 1997, was
approximately $35,408,056, based on the last sale price as reported by NASDAQ.
As of March 17, 1997, the registrant had 8,648,768 shares of common stock
outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The following documents (or parts thereof) are incorporated by reference
into the following parts of this Form 10-K: Certain information required in Part
III of this Annual Report on Form 10-K is incorporated from the registrant's
Proxy Statement for the Annual Meeting of Stockholders to be held on May 22,
1997.
1
<PAGE> 2
PART 1
ITEM 1. BUSINESS
INTRODUCTION
Sight Resource Corporation (the "Company") is in business to manufacture,
distribute and sell eyewear and related products and services and as necessary,
to administer the business functions of providing vision related medical
services. The Company provides a complete range of eye care products and
services through integrated networks of opticians, optometrists and
ophthalmologists. The Company's services are provided primarily to persons with
common vision disorders, as well as to persons with sight-threatening
conditions. The Company's operations currently consist of 72 eye care centers, a
centralized optical laboratory and distribution center, two management service
organizations ("MSOs") and ten laser vision correction ("LVC") centers which the
Company has established in association with leading hospitals, ambulatory
surgery centers and ophthalmologists.
The Company's objective is to become the leading integrated provider of eye
care products and services in select, regional markets. To develop significant
regional integrated networks, the Company's business strategy focuses on (i)
acquiring and integrating the assets of regional multi-site eye care centers and
the practices of eye care professionals (optometrists and ophthalmologists),
(ii) employing or entering into management services contracts with these
professionals, (iii) continuing to market comprehensive and competitively priced
eye care programs to leading HMOs, insurance companies and other third party
payors in the Company's regional markets, (iv) expanding strategic affiliations,
for pathology co-management opportunities, with select hospitals, ambulatory
surgery centers and eye care professionals and (v) continuing to market and
provide access to LVC services through the Company's eye care centers.
The Company believes that its integrated approach to eye care provides
significant advantages, benefits and opportunities to patients, providers and
payors. Patients benefit from the convenience of eye care products and services
delivered at a single location. Eye care professionals benefit from the
supplemental management and administrative services and resources provided by
the Company, permitting them to continue to dedicate their time and effort to
their patients and professional practices. Payors benefit from the Company's
ability to conveniently provide a complete range of eye care products and
services with high quality and low cost.
THE PRIMARY EYE CARE INDUSTRY
Primary Eye Care Population. Eye care professionals and organizations
recommend periodic eye examinations for all Americans. More than 150 million
Americans, or approximately 60% of the nation's population, use eyeglasses or
contact lenses to correct common refractive vision disorders and, in 1995, more
than 90 million of these persons purchased corrective eyewear. The population
for corrective eyewear has grown consistently over the last five years and the
demographic trends of an aging population are expected to generate increased
demand for corrective eyewear and optical services. In addition to refractive
vision disorders, each year many Americans also require medical or surgical eye
care services, such as treatment for cataracts, glaucoma and retinal disorders.
According to industry sources, ophthalmic surgeons perform more than 3 million
surgical procedures in the United States per year.
Primary Eye Care Market. Industry sources estimate that over $17 billion is
annually spent on eye care products and services, including eyeglasses, contact
lenses and professional eye care services. Of this, a total of approximately $13
billion is spent on sales of eyeglasses and contact lenses and approximately $4
billion is spent on eye examinations and related services performed by
opticians, optometrists and ophthalmologists. Approximately $4 billion of these
eyewear sales are associated with managed primary eye care programs.
2
<PAGE> 3
Primary Eye Care Providers. Eye care services in the United States are
delivered through a fragmented system of local providers, including individual
or small groups of opticians, optometrists and ophthalmologists. The Company
estimates that opticians, optometrists, retail optical chains and multi-site eye
care centers are the primary eye care providers to approximately 82% of the
population with common vision disorders. According to industry sources,
approximately 65,000 opticians, 31,000 optometrists and 16,500 ophthalmologists
are actively involved in eye care in the United States today.
Eye Care Trends. Concerns over the accelerating costs of healthcare in
general, including eye care, have resulted in the increasing role of managed
care in the eye care industry and a decline in the traditional fee-based eye
care product and service market. Managed care, which typically involves a third
party (frequently the payor) assuming responsibility for ensuring that eye care
is provided in a high quality, cost-effective manner, has reduced the
competitive position of many eye care professional groups and individual
practices. Many of these practices lack the capital to expand, develop
information systems and purchase new technologies. Many also have higher
operating costs and do not have formal ties with other providers nor the ability
to offer a variety of eye care services. In order to remain competitive in the
changing healthcare environment, eye care professionals increasingly are
affiliating with larger organizations which offer skilled and innovative
management, access to payors and their enrollees, sophisticated information
systems, greater capital resources and more efficient cost structures.
Approximately 40 million Americans currently receive primary eye care benefits
via third party payor programs. The Company believes that third party payors
increasingly will prefer to contract with a single provider for complete primary
eye care services within selected geographic areas.
Recent Eye Care Developments. The eye care industry is characterized by
rapid technological changes, including advances in medical device and ophthalmic
laser technologies and developments of alternative surgical techniques or new
pharmaceutical products. In October 1995, the United States Food and Drug
Administration (the "FDA") approved the use of an ophthalmic excimer laser to
correct nearsightedness. LVC is a surgical procedure which, utilizing an
ophthalmic excimer laser system, involves the removal of a microscopic layer of
the cornea. This procedure changes the curvature of the cornea and allows the
eye to focus light properly, resulting in improved vision. For the majority of
nearsighted patients this procedure can eliminate the need to wear eyeglasses or
contact lenses to correct their nearsightedness. It is estimated that in 1996
approximately 70,000 to 100,000 LVC procedures were performed in the United
States. Lasers for the correction of farsightedness and astigmatism are
currently undergoing FDA-required clinical testing.
ACQUISITION STRATEGY
The Company has an acquisition strategy to acquire and integrate the assets
of multi-site eye care centers and the practices of eye care professionals and
to employ or enter into management services contracts with these professionals.
This strategy includes both expanding existing regional markets and entering new
regional markets:
Expand Existing Regional Markets. The Company plans to expand its
business in the markets where it currently operates, particularly to
broaden the delivery of services offered in such markets. Acquisitions in
existing markets (i) permit the Company to effect economies of scale and
realize other operating efficiencies, (ii) provide the Company with the
opportunity to expand its patient base and revenues without a proportionate
increase in administrative costs (iii) permit the Company to strategically
complement existing operations and (iv) permit the Company to compete more
effectively to provide managed primary eye care services in these markets.
3
<PAGE> 4
Enter New Regional Markets. The Company intends to enter into
additional regional markets by acquiring the assets of multi-site eye care
centers and eye care practices that may be well positioned to become
leaders in their regional markets. The Company will target acquisitions in
strategic markets that will serve as platforms from which the Company can
consolidate a given service area by making and integrating additional
"in-market" acquisitions.
The Company evaluates qualitative issues such as the medical professionals'
reputations in the local and national marketplace, medical professionals'
training, licensure and experience, Medicare and Medicaid compliance, billing
practices and operating history. Prior to entering any market, the Company
considers such factors as the local level of eye care competition, networking
and consolidation activity, the regulatory environment, patient-provider ratios
and the economic condition of the local market. The Company also considers
acquisitions of, or affiliations with, ambulatory surgical centers, specialty
eye hospitals and other complementary practices and services that are consistent
with its objective of being a leading integrated provider of eye care products
and services in select, regional markets.
CURRENT OPERATIONS
EYE CARE CENTERS
Effective January 1, 1995, the Company acquired the assets of Cambridge Eye
Associates ("Cambridge Eye"), an optometric practice which now operates 22
primary eye care centers, principally in Massachusetts. The assets and
liabilities of Cambridge Eye were acquired from a Company by the same name
(Cambridge Eye Associates, Inc.) owned by Elliot S. Weinstock, O.D. as sole
stockholder. Following the acquisition, Cambridge Eye entered into a management
services contract with Optometric Providers, Inc. ("Optometric Providers"), a
corporation established to employ the optometrists previously employed by the
acquired company. Effective July 1, 1995, the Company acquired the assets of
Douglas Vision World, Inc. ("Vision World"), a company operating eight primary
eye care centers in Rhode Island. The assets and liabilities of Vision World
were acquired from a Company by the same name (Douglas Vision World, Inc.) owned
by Kathleen Haronian, Lynn Haronian and Shirley Santoro. Following the
acquisition Vision World entered into a management services contract with
Optometric Care, Inc. ("Optometric Care"), a professional corporation
established to employ the optometrists previously affiliated with the acquired
Company. Effective July 1, 1996, the Company acquired the assets and liabilities
of three Companies, the E.B. Brown Optical Company, Brown Optical Laboratories,
Inc. and E.B. Brown Opticians, Inc. ("E.B. Brown"), all owned by Gordon and
Evelyn Safran. E. B. Brown Operates 42 eye care centers in Ohio and western
Pennsylvania. Independent Optometrists are associated with all E.B. Brown
Eyecare Centers; therefore, the Company does not record revenue from the
provision of vision related medical services at these locations. The Company may
add optometrists to the staffs of several of its eye care centers in Ohio and
Pennsylvania. To accomplish this, it may be necessary to enter into management
services contracts with professional corporations established to employ these
optometrists.
The Company's 72 eye care centers are located in major shopping malls,
strip shopping centers, urban locations and free-standing buildings and
generally are clustered within discrete market areas so as to maximize the
benefit of advertising strategies and to minimize the cost of supervising
operations. The Company's centers in Massachusetts, Rhode Island and Ohio are
leading providers of prescription and non-prescription eye care products and
services in those markets. In addition, the Company's eye care centers in New
Hampshire and Pennsylvania are leading providers in their local markets. Each
eye care center carries an extensive array of eyeglass frames ranging in price
from value models to designer collections. Lens and frame selections include a
variety of materials and styles. In addition to prescription eyewear, each eye
care center also carries fashion sunglasses and eyewear accessories. E.B.
Brown's eye care centers also offer audiology
4
<PAGE> 5
goods and services which are provided by audiologists who service many of E.B.
Brown's centers on a rotating schedule.
5
<PAGE> 6
Each eye care center in Massachusetts, New Hampshire and Rhode Island is
staffed by one or more licensed optometrists, a manager and a number of trained
eye care technicians and/or licensed opticians. The Company intends to add
optometrists to several of its eye care centers in Ohio and Pennsylvania.
CENTRALIZED OPTICAL LABORATORY AND DISTRIBUTION CENTER
To meet the volume needs of the eye care centers for certain prescription
eyeglass lenses and the rapid delivery needs of each center's customers, the
Company operates a centralized optical laboratory and distribution center in
Holliston, Massachusetts. In February of 1997 the Company discontinued the
operations of a centralized optical laboratory and distribution facility
operated by E.B. Brown in Cleveland, Ohio, and consolidated its operations with
those at the Holliston facility. The centralized optical laboratory in Holliston
now provides complete laboratory services to all of the Company's eye care
centers, including polishing, cutting and edging, tempering, tinting and coating
of ophthalmic lenses. The distribution center provides and maintains a central
inventory of all accessories and supplies necessary to operate the primary eye
care centers, as well as "ready made" eye care products, including contact
lenses and related supplies. The inventory of eyeglass lenses, frames, contact
lenses, accessories and supplies is acquired through a number of sources,
domestic and foreign. The Company is not dependent on any one supplier.
Management believes that the centralized optical laboratory and distribution
center has the capacity to accommodate additional multi-site eye care centers.
MANAGEMENT SERVICES CONTRACTS
In states which allow the Company to employ optometrists and
ophthalmologists, the Company plans on providing medical services directly.
otherwise, the Company will enter into management services contracts with
optometrists, ophthalmologists and/or a professional corporation ("PC") which
will provide the medical service. The Company's wholly owned subsidiaries,
Cambridge Eye and Vision World entered into a management services contract with
optometric providers and optometric care, respectively. Accordingly, Cambridge
Eye operates as the maintenance service organization ("MSO") for optometric
providers and vision world operates as the MSO for optometric care. Cambridge
Eye and Vision World, as MSOs, have exclusive decision making authority for the
ongoing major operations of optometric providers and optometric care,
respectively, with the exception of the provision of medical services. Pursuant
to these management services contracts, the MSOs provide management,
administrative, marketing and related services to Optometric Providers and
Optometric Care. As a result, the Company is involved in the daily on-site
financial and administrative management of these optometric practices and
provides various other services to the practices from time to time, including
legal, financial reporting, treasury, human resources and insurance assistance.
The Company's goals in providing such services are to (i) improve the
performance of these optometric practices in these non-professional activities,
(ii) allow the optometrists employed by or associated with these practices to
more fully dedicate their time and efforts toward their professional practice
activities, and (iii) afford the Company expanded service capabilities, and, for
itself and on behalf of the optometric practices, capitalize on opportunities
for contracting with third party payors and their intermediaries, including
managed care providers.
Pursuant to the management service contracts, the Company (in the form of
its wholly owned subsidiaries acting as MSOs), among other things, (i) act as
the exclusive business manager and administrator of all business and
administrative functions and services associated with the provision of the
professional services, (ii) order and purchase all professional and office
inventory and supplies and arrange for the availability of the same, (iii)
maintain files and records, (iv) provide or arrange for the provision of
technical and ancillary service and support personnel, (v) establish, operate
and maintain bookkeeping, accounting, billing and collection systems, (vi)
render advice concerning the marketing of services, (vii) develop and administer
benefit plans for the professionals and (viii) render such other business and
financial management,
6
<PAGE> 7
consultation and advice as may reasonably be needed from time to time by the
practice in connection with its provision of professional services.
7
<PAGE> 8
The service fees payable to the Company by the affiliated practices under
the management services contracts vary based on the cost, nature and amount of
services provided, and may be adjustable or subject to renegotiation from time
to time. Service fees payable under existing and future contracts are subject to
the requirements of applicable laws, rules and regulations and negotiations with
individual professional practices.
Under the management services contracts, the affiliated practices retain
the responsibility for, among other things, (i) hiring and compensating
professionals, (ii) ensuring that professionals have the required licenses,
credentials, approvals and other certifications needed to perform their duties
and (iii) complying with applicable federal and state laws, rules and
regulations. In addition, the affiliated practices exclusively control all
aspects of professional practice and the delivery of professional services.
MANAGED PRIMARY EYE CARE
In 1993, about half of all Americans insured through their employers were
in a managed care plan, compared to 73% in 1995, according to an article in the
journal Health Affairs. The trend towards managed care has had a direct impact
on how primary eye care is delivered in the United States.
Industry sources estimate that managed primary eye care now has a 30% share
of the U.S. eyewear market. In the early 1990's, managed primary eye care
accounted for an estimated 20% of all eyewear purchases. The nationwide shift to
managed healthcare in general has been the main factor for this growth. NINETY
ONE PERCENT of all health maintenance organizations ("HMOs") best selling
benefit packages include a covered routine eye examination. These trends
continued throughout 1996, indicating that managed primary eye care's share of
eyewear and primary eye care should continue to grow.
Over the past few years eyeglasses have become a fashion item, driving up
their cost and shortening their replacement interval. At the same time, eyewear
is one of the least expensive healthcare benefits an employer can provide
employees. With these two fundamentals factors, employers and employees alike
are realizing the importance of a covered eyewear benefit. Since only 14.7% of
HMOs best selling packages cover an eyewear component (eyeglasses and contact
lenses), benefit programs which include eyewear represent an extraordinary
opportunity for growth within managed primary eye care. An eyewear benefit is
particularly important to younger workers who, because they enjoy good health,
often feel that their benefits package does not provide them with a tangible
benefit (such as new eyeglasses or contact lenses).
To address the expanding enrollment of patients in managed primary eye care
programs and the resulting patient flow to designated providers of these managed
primary eye care services, in early 1997 the Company created its SightCare
division. SightCare is responsible for developing innovative programs for third
party payors, securing new contracts for providing managed primary eye care
services, and ensuring the consistency and quality of managed primary eye care
products and services delivered by the Company.
SightCare is being introduced in the New England region in the first half
of 1997. As of December 31, 1996, the Company provided managed primary eye care
benefits to more than 25 organizations in New England, including private
companies, unions and leading HMOs. The Company intends to offer the SightCare
program in its Ohio and western Pennsylvania markets during the second half of
1997. Because of the Company's ability to deliver consistent, quality eyewear
and primary eye care at competitive prices, the Company believes SightCare will
achieve a leadership position in managed primary eye care in its markets. The
Company's buying power, centralized laboratory, in-center optometrists, and
broad outreach within its markets, position it to compete for managed primary
eye care business.
8
<PAGE> 9
LASER VISION CORRECTION SERVICES
Industry studies indicate that 60 to 70 million Americans are nearsighted
and that more than 90% of these people have a refractive disorder that falls
within the LVC treatment parameters approved by the FDA. Industry sources
estimate that approximately 70,000 to 100,000 LVC procedures for nearsighted
patients were performed in the U.S. in 1996, the first full year in which the
procedure was approved for use in this country. LVC for farsightedness and
astigmatism is currently undergoing FDA-required clinical testing. As new
technologies or procedures are approved for refractive correction, the Company
intends to incorporate these technologies and procedures into the services
provided by the Company.
The Company has established ten LVC centers in association with selected
hospitals, ambulatory surgery centers and private practice facilities. These LVC
surgical providers generally have a high level of name recognition and
reputation within the ophthalmic community and among prospective patients for
LVC which, in turn, supports the Company's efforts to market its LVC centers. By
affiliating with the Company, these LVC surgical providers benefit by having a
convenient way of participating in LVC without incurring the substantial capital
expenditures or the risk of technological obsolescence. The LVC surgical
providers also benefit from the Company's ability to acquire, counsel and refer
patients for LVC services.
LVC centers are established in compliance with applicable law and,
generally, pursuant to a written LVC center agreement between the Company and
the provider. The Company's obligations pursuant to such agreements typically
include: furnishing the laser system to be used for the delivery of LVC,
therapeutic and related eye care services at the LVC center; maintenance,
repairs and upgrades to the laser system; and certain training and oversight of
medical, technical and administrative personnel involved in the delivery of
services at the center. The providers' responsibilities pursuant to such
agreements typically include: providing ophthalmologists to perform the LVC,
therapeutic and related eye care services to patients at the LVC center,
including performing LVC on qualified patients originated through the Company's
marketing efforts; furnishing suitable space and certain ancillary equipment,
furniture and supplies for the lvc center's operations; and providing
administrative, nursing and technical support for the LVC center.
The LVC center agreements also generally provide for the Company to pay the
providers for certain services associated with each LVC procedure performed by
the provider on a patient generated through the Company's marketing efforts. In
addition, the provider pays the company an access fee for use of the laser
system to perform lvc or therapeutic procedures on patient generated by such
provider. Community-based ophthalmologists which also access the lvc center pays
the Company an access fee for use of the laser.
The Company has established a model for the delivery of LVC services. The
Company's LVC strategy is based upon generating and controlling patient flow,
and delivering LVC services through its primary eye care centers. The Company
believes that generating and controlling patient flow is the key to building a
successful LVC business. The Company's LVC strategy is based upon the approach
of delivering LVC services through its primary eye care centers. Delivering LVC
services through its primary eye care centers (i) provides the Company
significant and direct access to a large percentage of the population eligible
for LVC, (ii) provides prospective patients with local access to information
concerning LVC and to pre-operative assessments, (iii) offers patient
convenience to pre- and post-operative examinations that are part of the LVC
procedure, (iv) differentiates the Company's primary eye care centers in their
markets, and (v) adds only an incremental expense to existing optical and
optometric marketing costs. By offering LVC through its primary eye care
centers, the Company can offer LVC at lower prices than most of its competitors.
While cost may not have been an important factor to early adopters (i.e. that
segment of the market quick to accept and purchase new products and services),
it should provide the Company an advantage as LVC results generate wider
interest in the treatment and price comparison becomes more prevalent.
9
<PAGE> 10
MARKETING
As an integrated provider of eye care products and services in regional
markets, the Company makes use of various media to market its products and
services, including LVC:
ADVERTISING. The Company uses newspaper, magazine, television, radio,
direct mail and other advertising to reach prospective, as well as
existing, customers. Advertisements emphasize the Company's benefits to the
eyewear public, such as value pricing, product promotions, convenience of
location, customer service and knowledgeable salespersons. In-house
optometric examinations by licensed optometrists are also emphasized in
advertising, subject to regulatory requirements.
IN-CENTER MARKETING. The Company's eye care centers and LVC centers
are designed to be attractive and customer oriented. In its eye care
centers, the Company prepares and revises point-of-purchase displays, which
convey promotional messages to customers upon arriving at the center.
Visual merchandising techniques are employed to draw attention to products
displayed in the eye care centers. In addition, to market the Company's LVC
services in its eye care centers in New England, the Company shows
customers educational videotapes, provides take-home brochures and uses
LVC-specific point-of-purchase displays. As the Company introduces LVC
services to its eye care centers in Ohio and Pennsylvania, similar
strategies will be employed.
PERSONALIZED CONSULTATIONS. Each eye care center is staffed by a
manager and a number of trained eye care technicians and/or licensed
opticians, each of whom is trained to provide personalized consultation to
customers regarding the Company's eye care products and services. In New
England, every eye care center provides our patients with access to one or
more licensed optometrists who are similarly trained. Similar access is
planned for the eye care centers in Ohio and Pennsylvania.
QUARTERLY CATALOGS. The Company mails a quarterly catalog to customers
in New England who are in its marketing database. This database consist of
individuals who have utilized the services of the Company and its
affiliated professionals over the last several years. The catalog includes
educational, promotional and marketing information about the Company's
products and services, including LVC. The Company is exploring the
feasibility of expanding this program to its customers in Ohio and
Pennsylvania in the coming year.
FINANCING ARRANGEMENTS. The Company has arranged for the availability
of third-party financing vehicles for customers to purchase the Company's
products and services, including LVC.
MANAGED CARE. The Company markets its comprehensive and competitively
priced primary eye care programs to leading HMOs, insurance companies and
other third party payors in the Company's regional markets. The Company's
marketing strategy towards these organizations stresses its regional
coverage, its complete range of eye care products and services and its
commitment to quality and service. In 1997 the Company will introduce its
new SightCare programs in New England. The Company intends to offer this
program in all of its markets.
COMPETITION
The Company experiences competition regarding the acquisition of the assets
of, and the provision of management services to, eye care centers and practices.
Several companies, both publicly and privately held, that have established
operating histories and greater resources than the Company are pursuing the
acquisition of the assets of general and specialty practices and the management
of such practices.
10
<PAGE> 11
Eye care practices affiliated with the Company will compete with other
local eye care practices as well as managed care organizations. The Company
believes that changes in governmental and private reimbursement policies and
other factors have resulted in increased competition for consumers of eye care
services. The Company believes that cost, accessibility and quality of services
are the principal factors that affect competition.
The optical industry is highly competitive and includes chains of retail
optical stores, multi-site eye care centers, and a large number of individual
opticians, optometrists, and ophthalmologists who provide professional services
and/or dispense prescription eyewear. Since retailers of prescription eyewear
generally service local markets, competition varies substantially from one
location or geographic area to another. The Company believes that the principal
competitive factors affecting retailers of prescription eyewear are location and
convenience, quality and consistency of product and service, price, product
warranties, and a broad selection of merchandise, and that it competes favorably
in each of these respects.
The Company and its affiliated practices compete with other providers for
managed primary eye care contracts. The Company believes that trends toward
managed primary eye care have resulted in increased competition for such
contracts.
LVC competes with or supplements other surgical and non-surgical treatments
for refractive disorders, including eyeglasses, contact lenses, other types of
refractive surgery (such as radial keratotomy), corneal transplants and other
technologies currently under development. Other competitive factors which may
affect revenues include performance, pricing, convenience, ease of use, success
relative to alternative treatments and patient and general market acceptance.
Competition in providing LVC will come from entities similar to the Company
and from hospitals, hospital-affiliated group entities, physician group
practices and private ophthalmologists that, in order to offer LVC to existing
patients, purchase refractive lasers. Suppliers of conventional vision
correction alternatives (eyeglasses and contact lenses), such as optometric
chains, may also compete with the Company by purchasing laser systems and
offering LVC to their customers. Competition to provide LVC may lead to lower
prices for LVC, as has happened in some countries where the treatment has been
available for several years.
GOVERNMENT REGULATION
The Company and its operations are subject to extensive federal, state and
local laws, rules and regulations affecting the healthcare industry and the
delivery of healthcare, including laws and regulations prohibiting the practice
of medicine and optometry by persons not licensed to practice medicine or
optometry, prohibiting the unlawful rebate or unlawful division of fees and
limiting the manner in which prospective patients may be solicited.
The regulatory requirements that the Company must satisfy to conduct its
business vary from state to state, and, accordingly, the manner of operation by
the Company, the degree of control over the delivery of refractive surgery and
the level of revenues potentially generated by the Company may differ among the
states. The Company intends to comply with the various regulatory requirements.
It is possible that in certain states the proposed activities of the Company
will not be permissible on terms acceptable to the Company, in which case the
Company will not do business in such states. In the U.S., the Company has
established refractive surgery centers in affiliation with healthcare providers.
Various federal and state regulations may limit the financial and non-financial
terms of agreements with these healthcare providers, and the revenues
potentially generated by the Company may therefore differ among its various
healthcare provider affiliations. The Company intends to comply with such
regulations while seeking the most favorable financial and non-financial terms
in agreements with these healthcare providers.
11
<PAGE> 12
The FDA and other federal, state or local governmental agencies may amend
current, or adopt new, rules and regulations that could affect the use of
ophthalmic excimer lasers for laser vision correction and therefore adversely
affect the business of the Company.
Significant prohibitions against physician referrals have been enacted by
Congress. These prohibitions, commonly known as "Stark II," amended prior
physician self-referral legislation known as "Stark I" by dramatically enlarging
the field of physician-owned or physician-interested entities to which the
referral prohibitions apply. Effective December 31, 1994, Stark II prohibits a
physician form referring Medicare or Medicaid patients to an entity providing
"designated health services" in which the physician has an ownership or
investment interest, or with which the physician has entered into a compensation
arrangement. The designated health services include prosthetic devices, which
under applicable regulations and interpretations include one pair of eyeglasses
or contact lenses furnished after cataract surgery and intraocular lenses
provided at ambulatory surgery centers. The penalties for violating Stark II
include a prohibition on payment by these government programs and civil
penalties of as much as $15,000 for each violative referral and $100,000 for
participation in a "circumvention scheme." The Company believes that although it
will receive fees under the management service contracts for management
services, it is not in a position to make or influence referrals of patients. To
the extent the Company or any affiliated practice is deemed to be subject to the
prohibitions contained in Stark II for services, the Company believes its
activities fall within the permissible activities defined in Stark II,
including, but not limited to, the provision of in-office ancillary services.
ENVIRONMENTAL REGULATION
The Company's business activities are not significantly affected by
environmental regulations and no material expenditures are anticipated in order
for the Company to comply with environmental regulations. However, the Company
is subject to certain regulations promulgated under the Federal Environmental
Protection Act ("EPA") with respect to grinding, tinting, edging and disposing
of ophthalmic lenses and solutions.
PROPRIETARY PROPERTY
The Company has no licenses, patents or registered copyrights. The Company
does have various registered trademarks in the U.S., including "Sight Resource",
"Cambridge Eye Doctors" and "E.B. Brown Opticians".
EMPLOYEES
As of March 13, 1997, the Company had 488 employees. The Company intends to
hire additional key personnel it believes will be required for advancement and
expansion of the Company's activities.
The success of the Company's future operations depends in large part on the
Company's ability to recruit and retain qualified personnel over time. There can
be no assurance, however, that the Company will be successful in retaining or
recruiting key personnel.
BUSINESS RISKS AND CAUTIONARY STATEMENTS
When used in this Form 10-K and in future filings by the Company with the
Securities and Exchange Commission, in the Company's press releases and in oral
statements made with the approval of an authorized executive officer, the words
or phrases "will likely result", "are expected to", "estimate", "project" or
similar expressions are intended to identify "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, including those
discussed below, that could cause actual results to differ materially from
historical results and those presently anticipated or projected. The Company
wishes to caution readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made. The Company
wishes to advise readers that the factors listed below could affect the
Company's financial performance and could cause the Company's
12
<PAGE> 13
actual results for future periods to differ materially from any opinions or
statements expressed with respect to future periods in any current statements.
The Company will not undertake and specifically declines any obligation to
publicly release the result of any revisions which may be made to any
forward-looking statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or unanticipated
events.
There are a number of risks and uncertainties that could cause actual
results to differ materially from historical results and those presently
anticipated or projected. Among the most significant of such risks and
uncertainties are:
- The Company has a limited operating history. While the Company has had
experience with laser vision correction in the United Kingdom ("UK")
since 1993, laser vision correction was only approved in the U.S. in
late 1995. In addition, the Company entered the optical industry in
1995.
- The Company has a history of operating losses, has not yet been
profitable and may continue to incur significant operating losses for
the foreseeable future.
- There can be no assurance that the Company will be able to obtain
additional financing when needed or on terms acceptable to the
Company.
- The laser vision correction market, the optical industry and managed
primary eye care are highly competitive. The Company's current and
potential competitors include many larger companies with substantially
greater financial, operating, marketing and support resources than the
Company.
- There can be no assurance that laser vision correction will be
accepted by the U.S. population in any commercially significant
manner.
- The Company's plans for growth and expansion include acquisitions.
There can be no assurance that attractive acquisition candidates, or
the financing necessary for any such acquisitions, will be available
to the Company.
- There can be no assurance that the Company will be able to realize any
operating efficiencies from the purchase and consolidation of primary
eye care centers or optical chains.
- The Company is dependent on healthcare providers to perform laser
vision correction procedures and pre- and post-operative medical care.
There can be no assurance that the Company will be able to establish
or maintain beneficial relationships with such healthcare providers.
- The Company and its operations are subject to extensive federal, state
and local regulation, which could materially affect the Company's
operations.
- The Company's plan for growth and expansion includes growth of its
managed primary eye care contracts. There can be no assurance that
such contracts will be acquired or that existing contracts will be
expanded in any meaningful way.
13
<PAGE> 14
CORPORATE LIABILITY AND INSURANCE
The provision of professional eye care services entails an inherent risk of
professional malpractice and other similar claims. The Company does not
influence or control the practice of medicine or optometry by professionals or
have responsibility for compliance with certain regulatory and other
requirements directly applicable to individual professionals and professional
groups. As a result of the relationship between the Company and its affiliated
practices, the Company may become subject to some professional malpractice
actions under various theories. There can be no assurance that claims, suits or
complaints relating to professional services provided by affiliated practices
will not be asserted against the Company in the future. The Company believes
that the providers with which the Company enters into LVC center agreements or
other strategic affiliation agreements are covered by such providers'
professional malpractice or liability insurance. The Company may not be able to
purchase professional malpractice insurance, and may not be able to purchase
other insurance at reasonable rates, which would protect it against claims
arising from the professional practice conducted by providers. Similarly, the
use of laser systems in the Company's LVC centers may give rise to claims
against the Company by persons alleging injury as a result of the use of such
laser systems. The Company believes that claims alleging defects in the laser
systems it purchases from its suppliers are covered by such suppliers' product
liability insurance and that the Company could take advantage of such insurance
by adding such suppliers to lawsuits against the Company. There can be no
assurance that the Company's laser suppliers will continue to carry product
liability insurance or that any such insurance will be adequate to protect the
Company.
The Company maintains insurance coverage that it believes will be adequate
both as to risks and amounts. The Company believes that such insurance will
extend to professional liability claims that may be asserted against employees
of the Company that work on site at affiliated practice locations. In addition,
pursuant to the management services contracts, the affiliated practices are
required to maintain professional liability and comprehensive general liability
insurance. The availability and cost of such insurance has been affected by
various factors, many of which are beyond the control of the Company and its
affiliated practices.
There can be no assurance that the Company will be able to retain adequate
liability insurance at reasonable rates, or that the insurance will be adequate
to cover claims asserted against the Company, in which event the Company's
business may be materially adversely affected.
ITEM 2. DESCRIPTION OF PROPERTIES
Cambridge Eye, Vision World, and E.B. Brown lease the space for 22, 8 and
42, respectively, of the Company's eye care centers (which range in size from
approximately 1,100 to 6,300 square feet), under operating leases, which expire
as follows, exclusive of renewal options.
Year Number of leases expiring
- ---- -------------------------
1997 10
1998 12
1999 10
2000 14
2001 16
2002 and thereafter 2
In addition, the Company is currently in lease negotiations or is an at
will tenant for 8 eye care centers.
14
<PAGE> 15
The centralized optical laboratory and distribution center occupies
approximately 22,000 square feet of space leased by Cambridge Eye in an
industrial complex in Holliston, Massachusetts pursuant to a lease which expires
in 1998. In addition to the eye care centers and the centralized optical
laboratory and distribution center, the Company currently leases its executive
offices of approximately 5,400 square feet of space located at 67 South Bedford
Street, Burlington, Massachusetts 01803 pursuant to a lease which expires in
1998. The Company believes that its facilities are adequate for its present
needs and that suitable space will be available to accommodate its future needs.
ITEM 3. LEGAL PROCEEDINGS
The Company's subsidiaries are defendants in certain lawsuits alleging
various claims incurred in the ordinary course of business. These claims are
generally covered by various insurance policies, subject to certain deductible
amounts and maximum policy limits. In the opinion of management, the resolution
of existing claims should not have a material adverse effect, individually or in
the aggregate, upon the Company's business or financial condition.
Sight Resource Corporation is not currently a party to any claims, suits or
complaints, although there can be no assurance that such claims will not be
asserted against Sight Resource Corporation in the future. From time to time
Sight Resource Corporation has been party to claims, litigation or other
proceedings in the ordinary course of its business, none of which has been
material to the Company or its business.
There can be no assurance that future claims against the Company or any of
its subsidiaries will not have a material adverse effect on the Company, its
operations or financial condition.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted during the fourth quarter of the year ended
December 31, 1996.
15
<PAGE> 16
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
MARKET FOR COMPANY'S COMMON EQUITY
The Company's Common Stock and the IPO Warrants began trading on NASDAQ on
March 31, 1993 under the symbols "VISN" and "VISNW", respectively. The Company's
IPO Warrants expired on October 31, 1995. The Company also issued Warrants which
began trading on NASDAQ on August 25, 1994 under the symbol "VISNZ". The
following table sets forth for the periods indicated, the high and low sales
prices for the Common Stock, IPO Warrants and Warrants as reported by NASDAQ:
<TABLE>
<CAPTION>
COMMON STOCK WARRANTS IPO WARRANTS
--------------- ------------- ----------------
HIGH LOW HIGH LOW HIGH LOW
---- --- ---- --- ---- ---
<S> <C> <C> <C> <C>
1996:
First Quarter 11 7 7/8 5 1/4 2 15/16 - -
Second Quarter 9 1/8 6 1/2 4 2 11/16 - -
Third Quarter 7 1/8 4 3/4 3 5/16 2 3/16 - -
Fourth Quarter 6 3/4 4 1/2 2 7/8 1 1/8 - -
1995:
First Quarter 6 5/8 4 1/8 2 1 1 3/8
Second Quarter 7 3/4 5 7/8 2 3/4 1 5/8 1 7/16 5/8
Third Quarter 9 7/8 7 1/4 4 3/4 2 1/2 2 7/8 1 3/16
Fourth Quarter 11 1/4 6 5 5/8 3 1/4 2 1/4 * 1*
</TABLE>
* High and low sales price through the expiration date on October 31, 1995.
The Common Stock, IPO Warrants, and Warrants have been quoted on the
NASDAQ-National Market System ("NASDAQ-NMS") since August 25, 1994. Prior to
that time, the Common Stock and IPO Warrants were quoted on the NASDAQ-small cap
market.
During the third quarter, the Company issued 521,997 unregistered shares of the
Company's Common Stock related to the acquisition of E.B. Brown. The holders of
these unregistered shares have the same dividend and voting rights as all other
common stock holders.
The Company has not paid dividends to its stockholders since its inception and
does not plan to pay cash dividends in the foreseeable future. The Company
currently intends to retain earnings, if any, to finance the growth of the
Company. As of March 17, 1997, there were 279 and 20 holders of record of the
Company's Common Stock and Warrants, respectively. There are over 4,205
beneficial owners of the Company's Common Stock.
16
<PAGE> 17
ITEM 6. SELECTED FINANCIAL DATA
(In thousands, except per share amounts)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31 1996 (1,2) 1995 (3) 1994 1993 1992 (4)
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues $ 29,987 $ 18,240 $ 529 $ 155 $ --
Net loss (see note 1) (5,850) (4,888) (2,945) (1,530) (48)
Net loss per common share (0.78) (0.89) (0.94) (0.74) (.04)
Weighted average number of
common shares outstanding 7,523 5,488 3,122 2,057 1,307
BALANCE SHEET DATA:
Working capital (deficiency) $ 7,774 $ 5,325 $ 9,787 $ (690) $ (478)
Total assets 31,430 23,249 13,911 5,210 863
Non-current liabilities 1,876 1,703 -- -- --
Stockholders' equity 22,766 16,445 13,364 3,419 169
</TABLE>
1. Includes write-down for impairment of ophthalmic equipment of $2,622 in
1996.
2. Effective July 1, 1996, the Company purchased certain assets and assumed
certain liabilities of The E.B. Brown Optical Company and Brown Optical
Laboratories, Inc. and acquired by merger E.B. Brown Opticians, Inc.
(collectively "EB Brown"). EB Brown operates 42 eye care centers located
throughout Ohio and western Pennsylvania which provide optometric and
audiology goods and services to persons with vision and hearing disorders.
3. Effective January 1, 1995 and July 1, 1995 the Company purchased
substantially all the assets of Cambridge Eye Associates, Inc. and Douglas
Vision World, Inc. respectively. During 1995, these companies combined had
a practice of 29 optometric offices throughout New England providing
comprehensive vision care services to residents of this region.
4. Represents activity for the period from the date of inception of
Predecessor Partnership of April 29, 1992, to December 31, 1992.
Substantially all of the business of the Predecessor Partnership was
acquired by the Company in exchange for 861,900 shares of Common Stock on
November 30, 1992.
17
<PAGE> 18
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATION
OVERVIEW
Sight Resource Corporation (the "Company") IS IN BUSINESS TO MANUFACTURE,
DISTRIBUTE AND SELL EYEWEAR AND RELATED PRODUCTS AND SERVICES AND AS NECESSARY
TO ADMINISTER THE BUSINESS FUNCTIONS OF PROVIDING VISION RELATED MEDICAL
SERVICES. THE COMPANY provides a complete range of eye care products and
services through integrated networks of opticians, optometrists and
ophthalmologists. The Company's services are provided primarily to persons with
common vision disorders, as well as to persons with sight-threatening
conditions. The Company's operations currently consist of 72 eye care centers, a
centralized optical laboratory and distribution center, two management service
organizations ("MSOs") and ten laser vision correction ("LVC") centers which the
Company has established in association with leading hospitals, ambulatory
surgery centers and ophthalmologists.
In October 1995, the FDA first approved the use of one manufacturer's
excimer laser for the treatment in the United States of nearsightedness using
LVC. In March 1996, the FDA approved a second manufacturer's excimer laser for
the same treatment. The Company had commenced consolidation of its United
Kingdom operations during the third quarter of fiscal 1995 and, following the
FDA's initial approval, had fully discontinued these operations by the fourth
quarter of fiscal 1995.
The Company's objective is to become the leading integrated provider of eye
care products and services in select, regional markets. To develop significant
regional integrated networks, the Company's business strategy focuses on (i)
acquiring and integrating the assets of regional multi-site eye care centers and
the practices of eye care professionals (optometrists and ophthalmologists),
(ii) employing or entering into management services contracts with these
professionals, (iii) continuing to market comprehensive and competitively priced
eye care programs to leading HMOs, insurance companies and other third party
payors in the Company's regional markets, (iv) expanding strategic affiliations,
for pathology co-management opportunities, with select hospitals, ambulatory
surgery centers and eye care professionals and (v) continuing to market and
provide access to LVC services through the Company's eye care centers.
The Company believes that its integrated approach to eye care provides
significant advantages, benefits and opportunities to patients, providers and
payors. Patients benefit from the convenience of eye care products and services
delivered at a single location. Eye care professionals benefit from the
supplemental management and administrative services and resources provided by
the Company, permitting them to continue to dedicate their time and effort to
their patients and professional practices. Payors benefit from the Company's
ability to conveniently provide a complete range of eye care products and
services with the highest quality at the lowest cost.
1996 AS COMPARED WITH 1995
Revenue. The Company generated net revenue of approximately $30.0 million during
the year ended December 31, 1996, from the operation of its 72 eye care centers
and ten laser vision correction centers in the United States as compared to net
revenue of approximately $18.2 million from its 29 eye care centers and its
network of laser vision correction centers in the United Kingdom ("UK") for the
same period in 1995. Of the $11.8 million, or 64.4%, increase in net revenue for
the year ended December 31, 1996 as compared to the year ended December 31,
1995, $7.4 million relates to the additional forty-two eye care centers acquired
effective July 1, 1996. The remaining increase of $4.4 million relates to a full
year of revenue from the Vision World acquisition as well as the Company's first
full year of LVC services in the U.S.
18
<PAGE> 19
Cost of Revenue. Cost of revenue decreased as a percent of net revenue from
44.7% (approximately $8.1 million) for the year ended December 31, 1995, to
39.5% (approximately $11.8 million) for the year ended December 31, 1996. The
decrease as a percentage of net revenue is attributable to an increase in LVC
procedures as well as manufacturing efficiencies realized at the Company's
central lab. Cost of revenue for the years ended December 31, 1996 and 1995
principally consisted of (i) the cost of manufacturing, purchasing and
distributing optical products to its customers and (ii) the cost of delivering
LVC, including depreciation and maintenance on excimer lasers.
Selling, General and Administration Expenses. Selling, general and
administration expenses were approximately $21.6 million and $15.3 million for
the years ended December 31, 1996 and 1995, respectively. The increase primarily
relates to payroll and facility costs incurred in operating additional eye care
centers in 1996 as compared to 1995. Selling, general and administrative
expenses, as a percentage of net revenue, declined from 83.7% for the year ended
December 31, 1995, to 72.1% for the year ended December 31, 1996. This decrease
is a result of operating efficiencies which the Company began to realize from
the acquisition and expansion of multi-site eye care centers and an increase in
LVC revenue.
Impairment of ophthalmic equipment. During the fourth quarter of 1996 the
Company recognized a $2.6 million write down due to impairment of ophthalmic
equipment. Operating losses sustained during 1996 from the operation of this
equipment coupled with anticipated future operating losses over the remaining
depreciable life of the equipment WHICH WERE BASED UPON OPERATING HISTORY AND A
RECENT INDUSTRY REPORT INDICATING A SLOWER THAN EXPECTED GROWTH IN LVC, resulted
in the Company's decision to recognize the impairment IN THE FOURTH QUARTER
1996. THE FAIR VALUE OF THE EQUIPMENT IS BASED UPON RECENT PUBLICATIONS IN
OPHTHALMIC TRADE JOURNALS, OFFERS FROM THIRD PARTIES, AS WELL AS RECENT SALES OF
SIMILAR EQUIPMENT. SINCE THE COMPANY HAS NO OTHER SIGNIFICANT TANGIBLE OR
INTANGIBLE ASSETS ASSOCIATED WITH LVC, THE COMPANY BELIEVES THE IMPAIRMENT
RELATES ONLY TO OPHTHALMIC EQUIPMENT.
Other Income and Expenses. Interest income totaled approximately $499,000 and
$387,000 for the years ended December 31, 1996 and 1995, respectively. This
increase resulted from the investment of a higher average cash and cash
equivalents balance during 1996 as compared to 1995. Interest expense remained
comparable at approximately $248,000 and $253,000 for the years ended December
31, 1996 and 1995, respectively.
The Company also recorded a $150,000 foreign currency translation gain on the
liquidation of the UK business at the close of 1995.
Net Loss. The Company realized a net loss of approximately $5.9 million ($0.78
per share) and $4.9 million ($0.89 per share) for the years ended December 31,
1996 and 1995, respectively. The increase in net loss is primarily attributable
to the $2.6 million impairment of ophthalmic equipment recognized in the fourth
quarter of 1996 offset by an increase in volume of laser vision correction
services as well as six months of operations of the forty-two eye care centers
acquired effective July 1, 1996.
1995 AS COMPARED WITH 1994
Revenue. Revenue for the year ended December 31, 1995 amounted to approximately
$18.2 million compared to $529,000 for the same period in 1994. The significant
increase resulted from revenue generated by the Company's newly acquired optical
chains.
19
<PAGE> 20
Cost of Revenue. Cost of revenue for the year ended December 31, 1995 was
approximately $8.1 million as compared to approximately $928,000 for the same
period in 1994. The increase resulted from the inclusion of costs associated
with the sale of optical products by the Company's newly acquired optical
chains. The Company operates a centralized laboratory and distribution center
which provides comprehensive services to all of its eye care centers. Included
in cost of revenue in 1995 is the cost of manufacturing and delivering the
optical products to its customers in the U.S., as well as the costs to deliver
laser vision correction in the UK including depreciation and maintenance on
lasers of over $1.2 million. Included in cost of revenue in 1994 is depreciation
and maintenance on its excimer lasers in the UK, the Company's most significant
costs under the Company's joint venture agreement with British United Provident
Association ("BUPA").
Selling, General and Administrative Expenses. Selling, general and
administrative expenses were approximately $15.3 million and $2.5 million for
the years ended December 31, 1995 and 1994, respectively. The majority of the
increase relates to the costs of operating 29 eye care centers during 1995. In
addition, the Company continued to incur costs to develop and execute the
Company's U.S. business plan. Included in selling, general and administrative
expenses in 1995, were costs of occupancy and personnel at the 29 eye care
centers, advertising and marketing programs in the U.S. and UK, payroll and
office expenses in the U.S. and UK, severance and other costs associated with
closing the UK office, legal and accounting, and other general and
administrative expenses. In 1994, selling, general and administrative expenses
primarily consisted of costs incurred operating the network of BUPA/Sight
Resource laser vision correction centers in the UK.
Other Income and Expense. Interest income increased from approximately $183,000
for the year ended December 31, 1994 to approximately $387,000 for the
comparable period in 1995. This increase is a result of interest earned on the
invested proceeds received from the Company's second public offering in
September, 1994 and the exercise of the IPO Warrants in October 1995.
Interest expense for the year ended December 31, 1995 of approximately $253,000
represents interest on the revolving credit agreement and the long-term debt
which was assumed as part of the acquisition of Cambridge Eye. The Company also
recorded a $150,000 foreign currency translation gain on the liquidation of the
UK business at the close of 1995. In 1994, the Company had incurred $180,000 of
financing costs in conjunction with the issuance of the Bridge Notes and Class A
Warrants.
Net Loss. For the year ended December 31, 1995, the Company recorded a net loss
of approximately $4.9 million or $0.89 per share as compared to a net loss of
approximately $2.9 million or $0.94 per share for the same period in 1994.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1996, the Company had approximately $9.9 million in cash
and cash equivalents and working capital of approximately $7.8 million in
comparison to approximately $8.0 million in cash and cash equivalents and
working capital of approximately $5.3 million as of December 31, 1995.
In 1996, the Company issued 1,775,000 shares of common stock to the public
for net proceeds of approximately $9.8 million. The Company anticipates using
the net proceeds for working capital and other general corporate purposes,
including acquisitions.
Effective July 1, 1996, the Company purchased certain assets and assumed
certain liabilities of E.B. Brown Opticians, Inc. ("E.B. Brown"), a Company
operating 42 eye care centers in Ohio and Western Pennsylvania. The purchase
price for E.B. Brown consisted of a payment of $4.0 million in cash, 521,997
shares of common stock issued (valued at approximately $1.9 million), 71,181
shares of common stock to be issued (valued at approximately $432,000) and $1.4
million in notes of which $400,000 is payable in September 1997 and $1.0 million
is payable March 1998. The cash consideration was funded with cash on hand.
20
<PAGE> 21
Acquiring multi-site eye care centers is a key component of the Company's
business strategy. By acquiring multi-site eye care centers, the Company gains
critical mass of locations ensuring that potential patients and third party
payors will have convenient access to a wider variety of eye care services. It
also allows the Company to deliver these services at considerable savings by
using existing corporate and operational infrastructure, which includes store
operations, MIS, manufacturing, purchasing, distribution and training. The
Company is currently evaluating potential acquisition candidates. Without
additional funding, the Company's rate of acquisition and size of acquisition
could be limited.
As of December 31, 1996, the Company had securities outstanding which
provide it with potential sources of financing as outlined below:
Securities Potential proceeds
- ------------------------------------------------- ------------------
Warrants 2,472,100 $14,800,000
Class A Warrants 85,000 500,000
Unit Purchase Options 215,000 3,700,000
IPO Representative Warrants 85,000 1,300,000
Representative Warrants 170,000 1,400,000
-----------
$21,700,000
===========
There can be no assurance that the Company will obtain any such proceeds
from the exercise of the above securities.
On February 20, 1997, the Company entered into a Credit Agreement (the
"Agreement") with a bank pursuant to which the Company can borrow $5 million on
a term loan basis and $5 million on a revolving credit basis, subject to certain
performance criteria. Such certain performance criteria include, among others,
financial condition covenants such as rolling EBITDA levels, indebtedness to
ebitda ratios, current ratio of 1:1 and minimum net worth ratios. The term loan
facility bears an interest rate of prime plus 1.5% or LIBOR plus 3% at the
borrowers election, and the revolving credit facility bears an interest rate of
prime plus 1.25% or LIBOR plus 2.75% at the borrowers election. These loans are
secured by all assets of the Company and its wholly owned subsidiaries. Amounts
borrowed under the Agreement will be used to refinance existing debt, finance
future acquisitions, provide ongoing working capital and for other general
corporate purposes. As part of the Agreement, the Company issued to the bank
warrants to purchase 150,000 shares of the common stock at a purchase price of
$4.625 per share. The warrants expire December 31, 2003.
The Company anticipates that its working capital and sources of capital,
such as the new credit facility, will be adequate to fund the Company's
currently proposed activities for at least the next twelve months. The Company
anticipates using financing vehicles such as bank debt, leasing, and other
sources of funding, such as additional equity offerings, to fund its operations.
There can be no assurance that the Company will be successful in obtaining funds
from any such sources. If additional funds are raised by issuing equity
securities, further dilution to the Company's stockholders may result. If
additional funds are not available, the Company may be required to delay
execution of its business plan.
21
<PAGE> 22
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Sight Resource Corporation:
We have audited the consolidated balance sheets of Sight Resource
Corporation and its subsidiaries as of December 31, 1996 and 1995, and the
related consolidated statements of operations, stockholders' equity, and cash
flows for each of the years in the three-year period ended December 31, 1996.
These consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Sight
Resource Corporation and its subsidiaries at December 31, 1996 and 1995, and the
results of their operations and their cash flows for each of the years in the
three-year period ended December 31, 1996 in conformity with generally accepted
accounting principles.
/s/ KPMG Peat Marwick LLP
KPMG Peat Marwick LLP
Boston, Massachusetts
February 28, 1997
22
<PAGE> 23
SIGHT RESOURCE CORPORATION
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31 1996 1995
- -----------------------------------------------------------------------------------------------
(in thousands)
ASSETS
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 9,924 $ 8,035
Accounts receivable, net of allowance of $353 and $277
1,405 662
Inventories 2,489 1,560
Prepaid expenses and other current assets 286 171
Assets held for sale (note 3) 458 --
-------- --------
Total current assets 14,562 10,428
-------- --------
Property and equipment, net (note 3) 4,935 5,778
-------- --------
Other assets:
Intangible assets (note 4) 11,768 6,908
Other assets 165 135
-------- --------
Total other assets 11,933 7,043
-------- --------
$ 31,430 $ 23,249
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Revolving note payable (note 6) $ 475 $ 475
Current portion of long term debt (note 6) 800 400
Accounts payable 1,843 1,727
Accrued expenses (note 5) 3,670 2,499
-------- --------
Total current liabilities 6,788 5,101
-------- --------
Non-current liabilities:
Long term debt, less current maturities (note 6) 1,600 1,000
Other liabilities 276 703
-------- --------
Total non-current liabilities 1,876 1,703
-------- --------
Commitments (note 7)
Stockholders' equity (note 8):
Preferred Stock, $.01 par value. Authorized 5,000,000
shares; no shares issued and outstanding -- --
Common stock, $.01 par value. Authorized 20,000,000
shares; issued and outstanding 8,648,768 and 6,346,615
shares in 1996 and 1995, respectively 86 63
Additional paid-in capital 37,510 25,794
Common stock issuable, 71,181 shares in 1996 (note 1(b)) 432 --
Accumulated deficit (15,262) (9,412)
-------- --------
Total stockholders' equity 22,766 16,445
-------- --------
$ 31,430 $ 23,249
======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
23
<PAGE> 24
SIGHT RESOURCE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 1994
- ----------------------------------------------------------------------------------------------------
(in thousands except for per share amounts)
<S> <C> <C> <C>
Net revenue $ 29,987 $ 18,240 $ 529
Cost of revenue 11,841 8,147 928
-------- -------- --------
Gross margin 18,146 10,093 (399)
Selling, general and administrative expense 21,625 15,265 2,492
Impairment of ophthalmic equipment (note 3) 2,622 -- --
-------- -------- --------
Total operating expenses 24,247 15,265 2,492
-------- -------- --------
Loss from operations (6,101) (5,172) (2,891)
-------- -------- --------
Other income (expense):
Interest income 499 387 183
Interest expense (248) (253) (48)
Other -- 150 (189)
-------- -------- --------
Total other income (expense) 251 284 (54)
-------- -------- --------
Net loss ($ 5,850) ($ 4,888) ($ 2,945)
======== ======== ========
Net loss per share ($ 0.78) ($ 0.89) ($ 0.94)
======== ======== ========
Weighted average number of common shares
outstanding 7,523 5,488 3,122
======== ======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
24
<PAGE> 25
SIGHT RESOURCE CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1996, 1995 AND 1994
- --------------------------------------------
(in thousands)
<TABLE>
<CAPTION>
ADDITIONAL COMMON CUMULATIVE TOTAL
COMMON STOCK PAID-IN ACCUMULATED STOCK TRANSLATION STOCKHOLDERS
SHARES PAR VALUE CAPITAL DEFICIT ISSUABLE ADJUSTMENT EQUITY
------ --------- ------------ ------------ --------- ----------- ------------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1993 2,287 $ 23 $ 5,002 ($ 1,579) $ -- ($ 27) $ 3,419
Proceeds from public offering, net of
offering costs 2,472 25 12,496 -- -- -- 12,521
Proceeds from exercise of IPO warrants 11 -- 73 -- -- -- 73
Issuance of Class A warrants -- -- 65 -- -- -- 65
Net loss -- -- -- (2,945) -- -- (2,945)
Cumulative translation adjustment -- -- -- -- -- 231 231
----- ---- -------- -------- ----- ------ --------
Balance, December 31, 1994 4,770 48 17,636 (4,524) -- 204 13,364
Issuance of common stock for
acquisitions 556 6 1,721 -- -- -- 1,727
Issuance of common stock for
equipment and other 64 -- 206 -- -- -- 206
Proceeds from exercise of warrants
(note 8) 955 9 6,221 -- -- -- 6,230
Proceeds from exercise of stock
options 2 -- 10 -- -- -- 10
Net loss -- -- -- (4,888) -- -- (4,888)
Cumulative translation adjustment -- -- -- -- -- (204) (204)
----- ---- -------- -------- ----- ------ --------
Balance, December 31, 1995 6,347 63 25,794 (9,412) -- -- 16,445
Proceeds from exercise of warrants -- -- 1 -- -- -- 1
Proceeds from public offering, net of
offering costs 1,775 18 9,816 -- -- -- 9,834
Issuance of common stock for 522 5 1,896 -- 432 -- 2,333
acquisitions
Proceeds from exercise of stock 5 -- 3 -- -- -- 3
options
Net loss -- $ -- -- (5,850) -- -- (5,850)
----- ---- -------- -------- ----- ------ --------
Balance, December 31, 1996 8,649 $ 86 $ 37,510 ($15,262) $ 432 $ -- $ 22,766
===== ==== ======== ======== ===== ====== ========
</TABLE>
See accompanying notes to consolidated fin --ancial statements.
25
<PAGE> 26
SIGHT RESOURCE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 1994
- ----------------------------------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Operating activities:
Net loss ($ 5,850) ($ 4,888) ($ 2,945)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 2,221 1,688 928
Impairment of ophthalmic equipment 2,622 -- --
Realization of foreign currency gain -- (150) --
Amortization of debt financing cost -- -- 65
Changes in operating assets and liabilities:
Accounts receivable (248) (1) (33)
Inventories 153 424 --
Prepaid expenses and other current assets (47) 75 (4)
Accounts payable and accrued expenses (1,408) (844) (1,294)
-------- -------- --------
Net cash used in operating activities (2,557) (3,696) (3,283)
-------- -------- --------
Investing activities:
Purchases of property and equipment (1,639) (1,948) (175)
Acquisition of subsidiaries (2,854) (2,363) --
Other assets (72) (4) (19)
-------- -------- --------
Net cash used in investing activities: (4,565) (4,315) (194)
-------- -------- --------
Financing activities:
Principal payments on Bridge Notes and long term debt (400) (400) (1,100)
Proceeds from sale of Bridge Notes and Class A warrants -- -- 1,100
Proceeds from exercise of warrants and stock options 4 6,240 73
Net proceeds from public offerings 9,834 -- 12,521
Payment of other liabilities (427) -- --
-------- -------- --------
Net cash provided by financing activities 9,011 5,840 12,594
-------- -------- --------
Effect of exchange rate changes on cash -- 12 74
-------- -------- --------
Net increase (decrease) in cash and cash equivalents 1,889 (2,159) 9,191
Cash and cash equivalents, beginning of period 8,035 10,194 1,003
-------- -------- --------
Cash and cash equivalents, end of period $ 9,924 $ 8,035 $ 10,194
======== ======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
26
<PAGE> 27
SIGHT RESOURCE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996, 1995 AND 1994
(1) THE COMPANY
(a) Nature of Business
The business of Sight Resource Corporation is to participate in the delivery of
a complete range of eye care products and services through integrated networks
of opticians, optometrists and ophthalmologists.
(b) U.S. Acquisitions
During 1995, the Company acquired two primary eye care chains, effective January
1, 1995 and July 1, 1995, respectively. The aggregate purchase price paid in
connection with the acquisitions consisted of (i) $2,660,000 in cash, (ii)
555,525 shares of common stock, (iii) the assumption of approximately $1,600,000
of net liabilities, and (iv) $660,000 payable over a 3 year period and $250,000
payable over 18 months, contingent upon the occurrence of certain future events.
The transactions were accounted for using the purchase method of accounting.
Effective July 1, 1996, the Company purchased certain assets and assumed certain
liabilities of The E.B. Brown Optical Company and Brown Optical Laboratories,
Inc. as well as entered into a merger with E.B. Brown Opticians, Inc. (together
"EB Brown") for approximately $4,000,000 in cash, 521,997 shares of common stock
issued, 71,181 shares of common stock to be issued and $1,400,000 in notes
payable over an eighteen month period. EB Brown operates forty-two eye care
centers located throughout Ohio and western Pennsylvania which provide
optometric and audiology goods and services to persons with vision and hearing
disorders. The transaction was accounted for using the purchase method of
accounting.
The results of operations of the three acquisitions have been included in the
consolidated financial statements from their respective dates of acquisition.
The excess of the purchase price and expenses associated with each acquisition
over the estimated fair value of the net assets acquired has been recorded as
goodwill.
The following unaudited pro forma results of operations gives effect to the
acquisitions as if all three transactions had occurred at the beginning of 1995
and the EB Brown acquisition had occurred at the beginning of 1996.
<TABLE>
<CAPTION>
(in thousands) 1996 1995
-------- --------
<S> <C> <C>
Revenue $ 37,834 $ 35,377
======== ========
Net loss ($ 5,202) ($ 4,570)
======== ========
Loss per share ($ 0.67) ($ 0.75)
======== ========
Weighted average number of common
shares outstanding 7,782 6,097
======== ========
</TABLE>
The above unaudited pro forma financial information reflects certain
adjustments, including amortization of goodwill, and an increase in the weighted
average shares outstanding. This pro forma information does not necessarily
reflect the results of operations that would have occurred had the acquisitions
taken place at the beginning of 1995 and 1996 and is not necessarily indicative
of results that may be obtained in the future.
27
<PAGE> 28
(c) UK Operations
While the Company's initial efforts focused on building a LVC delivery model in
the UK, the Company is now fully concentrating its attention and resources on
the growth opportunities in the United States. As a result, the Company fully
discontinued its UK operations in the fourth quarter 1995. The costs associated
with the discontinuance of UK operations is immaterial and is included in
operating expenses in 1995. The Company realized a foreign currency gain of
approximately $150,000 on the liquidation of the UK subsidiaries which is
included in other income at December 31, 1995.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a) Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the
Company, its wholly-owned subsidiaries and two professional corporations ("PCs")
in which the Company's subsidiaries assume the financial risks and rewards of
such entities through a management contract and a stock agreement. The Company
has no direct equity ownership in the PCs. All significant intercompany balances
and transactions have been eliminated.
In preparation of these consolidated financial statements in conformity with
generally accepted accounting principles, management of the Company has made
estimates and assumptions that affect the reported amounts of assets and
liabilities, such as accounts receivable, inventory impairment of property and
equipment and intangibles. Actual results could differ from those estimates.
(b) Foreign Currency Translation
Assets and liabilities denominated in foreign currencies are translated into
U.S. dollars at the exchange rate on the balance sheet date. Income and expense
items are translated at average rates of exchange prevailing during each period.
Translation adjustments are accumulated in a separate component of stockholders'
equity. Transaction gains and losses are included in the results of operations
and have not been material in any year. As described above, the UK operations
were discontinued as of December 31, 1995 and the assets and liabilities were
transferred to the U.S.
(c) Statement of Cash Flows
Cash and cash equivalents consist of cash in banks and short-term investments
with original maturities of three months or less.
(d) Financial Instruments
The carrying amount of cash and cash equivalents, accounts receivable, accounts
payable and accrued expenses approximate fair value because of the short
maturity of these items. The carrying amount of other long-term maturities
approximates fair value. The carrying amount of the Company's revolving line of
credit approximates fair value because the borrowing rate changes with market
interest rates.
(e) Revenue Recognition
Revenue and the related costs from the sale of eyewear are recognized at the
time an order is placed. The Company has fee for service arrangements with all
of its third party payors. Revenue is reported net of the contractual
allowances.
Under revenue sharing arrangements for refractive surgery where the Company is
not responsible for patient billing, the Company receives a specified payment
from the hospital or center for each refractive surgical procedure performed.
Accordingly, the Company recognizes revenue on a per procedure basis at the time
procedures are performed. Under revenue-sharing arrangements for refractive
surgery where the Company is responsible for the collection from the patient and
payment to the ophthalmologist and other operating costs, the total patient
charge is recorded as revenue with the corresponding expenses recorded in cost
of revenue.
28
<PAGE> 29
(f) Inventories
Inventories primarily consist of the costs of eyeglass frames, contact lenses,
ophthalmic lenses, sunglasses and other optical products and are valued at the
lower of cost (using the first-in, first-out method) or market.
(g) Property and Equipment
Property and equipment is stated at cost. The Company provides for depreciation
at the time the property and equipment is placed in service. The straight-line
method is used over the estimated useful life of the assets.
(h) Advertising
The Company expenses advertising costs as incurred.
(i) Intangible Assets
Intangible assets resulting from the business acquisitions consist of patient
lists, trademarks, non-compete agreement and the excess cost of the acquisition
over the fair value of the net assets acquired (goodwill). Certain values
assigned are based upon independent appraisals and are amortized on a straight
line basis over a period of 5 to 25 years. The Company assesses the
recoverability of unamortized intangible assets on an ongoing basis by comparing
anticipated operating profits and future, undiscounted cash flows to net book
value. In performing this analysis, management considers such factors as current
results, trends, and future prospects, in addition to other economic factors.
(j) Income Taxes
The Company follows the asset and liability method of accounting for income
taxes and records deferred tax assets and liabilities based on temporary
differences between the tax bases of assets and liabilities and their carrying
amounts for financial statement purposes.
(k) Deferred revenue
The Company offers a contact lens purchasing program in which, for a set fee,
customers may purchase contacts at discounted rates for a 12 month period. The
Company recognizes revenue from the sales of its contact lens purchasing program
on a monthly basis over the life of the program.
(l) Net Loss Per Share
Net loss per share of common stock is based on the weighted average number of
common shares outstanding. Common stock equivalents are not included in the
calculation because they are antidilutive.
(m) Reclassification
Certain reclassifications were made to the 1995 Consolidated Financial
Statements to conform to the 1996 presentation.
29
<PAGE> 30
(3) PROPERTY AND EQUIPMENT
Property and equipment consists of the following:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 USEFUL LIFE
- ------------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Land and building $ 87 $ -- 40 years
Ophthalmic equipment 2,921 7,425 3-5 years
Computer equipment 108 89 3 years
Furniture and fixtures 659 379 3 years
Leasehold improvements 1,698 261 Life of lease
Construction-in-progress 557 104
------ ------
6,030 8,258
Less accumulated depreciation 1,095 2,480
------ ------
Property and equipment, net $4,935 $5,778
====== ======
</TABLE>
During the fourth quarter of 1996, the Company recognized a $2,622,000 write
down due to impairment of ophthalmic equipment. Operating losses sustained
during 1996 from the operation of the equipment coupled with anticipated future
operating losses over the remaining depreciable life of the equipment resulted
in the Company's decision to recognize the impairment. The fair value of the
equipment is based upon recent publications in ophthalmic trade journals, offers
from third parties as well as recent sales of similar equipment.
Approximately $458,000 of the impaired ophthalmic equipment is held for sale and
accordingly presented as assets held for sale on the Company's balance sheet as
of December 31, 1996.
(4) INTANGIBLE ASSETS
Intangible assets consists of the following:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 USEFUL LIFE
- -----------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Goodwill $ 9,132 $ 4,201 20-25
-------
Patient lists 2,659 2,659 11-15
-------
Non-compete 120 -- 5
-------
Trademarks 713 413 15
------- -------
12,624 7,273
Accumulated amortization 856 365
-------
Total $11,768 $ 6,908
=======
</TABLE>
The useful lives of the above intangible assets are estimated based upon, among
other things, independent appraisals, history of operations acquired, terms of
agreements and industry standards.
30
<PAGE> 31
(5) ACCRUED EXPENSES
Accrued expenses consists of the following:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995
- ------------------------------------------------------------------------------
(in thousands)
<S> <C> <C>
Professional fees $ 220 $344
Payroll and related cost 1,263 676
Acquisition payments 303 387
Deferred revenue 303 286
Other 1,581 806
------ ------
$3,670 $2,499
====== ======
</TABLE>
(6) DEBT
Long term debt is as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995
- ----------------------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C>
Bank term loan, 8.875 % interest rate at December 31,
1996, repayable in quarterly installments of $100
through March 1998 followed by 4 quarterly installments
of $125, secured by all assets of one of the Company's
subsidiaries $1,000 $1,400
Unsecured notes payable, 7% interest rate, $400 due on
September 18, 1997 and $1,000 due on March 18, 1998;
due on demand if the Company's cash balance is less
than $2,800 1,400 --
------ ------
2,400 1,400
Less current maturities 800 400
------ ------
Long term debt, less current maturities $1,600 $1,000
====== ======
</TABLE>
The Company also has available a revolving credit facility in the amount of
$500,000 based on eligible accounts receivable and inventory balances which
bears interest at the bank's base rate plus 1.5% (10% at December 31, 1995 and
9.75% at December 31, 1996). As of December 31, 1996 and 1995, $25,000 was
unused.
On February 20, 1997, the Company entered into a Credit Agreement (the
"Agreement") with a bank pursuant to which the Company can borrow $5,000,000 on
a term loan basis and $5,000,000 on a revolving credit basis, subject to certain
performance criteria. These loans are secured by all assets of the Company and
its wholly owned subsidiaries. Amounts borrowed under the Agreement will be used
to refinance existing bank debt, finance future acquisitions, provide ongoing
working capital and for other general corporate purposes. As part of the
Agreement, the Company issued to the bank warrants to purchase 150,000 shares of
the common stock at a purchase price of $4.625 per share. The warrants expire
December 31, 2003. The warrants were accounted for as additional paid in capital
based upon the fair value of the securities. Fair market value was determined by
using the relationship of the interest rate charged with the warrants versus the
rate to be charged without the warrants. This value approximated that obtained
using the black scholes method.
31
<PAGE> 32
(7) COMMITMENTS
The Company has operating leases primarily for its primary eye care centers,
distribution center, corporate offices and certain equipment. The leases are
generally for periods of up to 10 years with renewal options at fixed rentals.
Certain of the leases provide for additional rentals based on sales exceeding
specified amounts.
The future minimum lease rental commitments for facilities and equipment for the
periods following December 31, 1996 are as follows:
(in thousands)
1997 $ 2,542
1998 2,179
1999 1,491
2000 1,189
2001 613
Thereafter 423
-------
$ 8,437
=======
Rental expenses charged to operations, including real estate taxes, common area
maintenance and other expenses related to the leased facilities and equipment,
were approximately $2,592,000, $1,750,000, $58,000 for fiscal years 1996, 1995
and 1994, respectively.
(8) STOCKHOLDERS' EQUITY
Preferred Stock
As of December 31, 1996 and 1995, the Company has authorized 5,000,000 shares of
preferred stock of $.01 par value of which none have been issued and
outstanding. The terms and conditions of the preferred stock, including any
preferences and dividends, will not be established until such time, if ever, as
such shares are in fact issued by the Company.
Common Stock
As of December 31, 1996 and 1995, the Company has authorized 20,000,000 shares
of common stock at $.01 par value. Common stock is entitled to dividends if
declared by the Board of Directors, and each share carries one vote.
In 1994, the Company issued 2,472,000 shares of common stock to the public for
net proceeds of approximately $12.5 million. The Company used the net proceeds
for working capital and other general corporate purposes, including
acquisitions.
In 1996, the Company issued 1,775,000 shares of common stock to the public for
net proceeds of approximately $9.8 million. The Company anticipates using the
net proceeds for working capital and other general corporate purposes, including
acquisitions.
Warrants
During the second half of 1995, the Company received net proceeds of
approximately $6,078,000 from the exercise of 929,140 IPO Warrants. Each IPO
Warrant entitled the holder to purchase one share of common stock at $6.75. On
October 31, 1995, the expiration date of the IPO Warrants, 3,110 IPO Warrants
expired unexercised.
32
<PAGE> 33
In connection with the Company's initial public offering, the Company sold to
the IPO Representative (at an aggregate price of $85), warrants to purchase up
to 85,000 IPO Units at an exercise price of $7.98 per IPO Unit at any time
during the four-year period commencing March 31, 1994. Each IPO Unit consists of
one share of common stock and one redeemable common stock purchase warrant,
which entitles the holder to purchase one share of common stock at a price of
$6.75. At December 31, 1996 and 1995, no IPO Units have been exercised.
In connection with the Company's private placement of Bridge Notes, the Company
issued 110,000 Class A Warrants. Each Class A Warrant entitles the holder to
purchase one share of common stock at a price of $6.00 and is exercisable at any
time through March 25, 1999. During 1995, 25,000 Class A Warrants were exercised
providing the Company with net proceeds of $150,000.
In connection with the Company's second public offering, the Company issued
2,472,500 redeemable common stock purchase warrants ("Z Warrant"). Each Z
Warrant entitles the holder to purchase one share of common stock at a price of
$6.00 and terminates on August 25, 1999, unless previously redeemed. The Z
Warrants are redeemable at the option of the Company at a price of $.05 per
warrant, upon 30 days written notice, provided that the closing price of the
common stock exceeds $9.50 for a period of 20 consecutive business days. During
fiscal 1995, 300 Z Warrants were exercised providing the Company with $1,800 in
proceeds. During the year ended December 31, 1996, 100 Z Warrants were exercised
providing the Company with $600 in proceeds.
In connection with the Company's second public offering, the Company sold to its
underwriter and a finder, 215,000 Unit Purchase Options (UPOs) at a price of
$.001 per UPO. Each UPO consists of one share of common stock and one redeemable
common stock purchase warrant, which entitles the holder to purchase one share
of common stock at a price of $7.20. The UPOs are exercisable for a period of
four years commencing August 25, 1995, at a price of $9.90. At December 31, 1996
and 1995, no UPOs have been exercised.
In connection with its third public offering in 1996, the Company sold to its
underwriter warrants to purchase an aggregate of 170,000 shares of the Company's
common stock at $8.45. At December 31, 1996, no warrants had been exercised.
Stock Option Plan
On November 30, 1992, the Company's Board of Directors and the stockholders
approved the Company's 1992 Employee, Director and Consultant Stock Option Plan
(the "Plan"). On April 26, 1994, the Board of Directors and the stockholders
approved the increase shares of common stock reserved for issuance under the
Plan to an aggregate of 1,000,000 shares. In March 1996 the Board recommended
and the stockholders subsequently approved, that an additional 500,000 shares of
common stock be reserved for issuance under the Plan. Under the Plan, incentive
stock options may be granted to employees of the Company. Non-qualified stock
options may be granted to consultants, directors, employees or officers of the
Company. Most options vest after two or three years from date of grant with a
maximum term of ten years.
In December, 1994 the Compensation Committee of the Board of Directors approved
a Stock Option Exchange Program (the "Program"). All employees and consultants
with stock options with exercise prices in excess of $4.40 per share were given
the election to cancel the existing option for new options at a per share price
of $4.40. Upon election all prior vesting was forfeited and the replacement
options began vesting on the exchange date on a schedule equal to the original
option being canceled. The $4.40 exercise price was in excess of the then
current fair market value of the share on the date of exchange. Options for a
total of 270,800 were canceled and reissued under the Program.
33
<PAGE> 34
The Company applies APB Opinion No. 25 and related interpretations in accounting
for the Plan. Accordingly, no compensation cost has been recognized. Had
compensation costs been determined consistent with FASB Statement No. 123, the
Company's net loss and loss per share would have been as follows:
<TABLE>
<CAPTION>
(in thousands) 1996 1995 1994
------- ------- -------
<S> <C> <C> <C> <C>
Net loss as reported ($5,850) ($4,888) ($2,945)
======= ======= =======
pro forma ($6,308) ($5,328) ($3,097)
======= ======= =======
Net loss per share as reported ($ 0.78) ($ 0.89) ($ 0.94)
======= ======= =======
pro forma ($ 0.84) ($ 0.97) ($ 0.99)
======= ======= =======
</TABLE>
The fair value of each option grant is estimated on the date of grant using the
Black-Schools option pricing model with the following weighted average
assumptions used for grants in 1996, 1995 and 1994, respectively: no dividends
expected in all years; expected volatility of 63.9% for all years; risk free
interest rates of 6.41%, 6.37% and 6.27%, respectively, and expected life of six
years for all years.
A summary of the stock option transactions follows:
<TABLE>
<CAPTION>
WEIGHTED
NUMBER OF AVERAGE
SHARES SHARES UNDER PRICE PER
AVAILABLE OPTION SHARE
----------- --------------- ----------------
<S> <C> <C> <C>
Balance, December 31, 1994 524,000 476,000 $5.00
Canceled 173,667 (173,667) 6.49
Granted (368,400) 368,400 5.21
Exercised -- (2,100) 4.40
-------- -------- -----
Balance, December 31, 1995 329,267 668,633 4.81
Increase in Plan 500,000 -- --
Canceled 8,200 (8,200) 5.41
Granted (228,400) 228,400 6.46
Exercised -- (20,700) 4.39
-------- -------- -----
Balance, December 31, 1996 609,067 868,133 $5.24
======== ======== =====
</TABLE>
There were 407,421 and 253,012 shares exercisable under the Plan at December 31,
1996 and 1995, respectively.
The weighted average fair value of options granted under the Plan was $3.95 and
$3.36 for the years ended December 31, 1996 and 1995, respectively.
The following table summarizes information about options outstanding as of
December 31, 1996:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
---------------------------------------- ----------------------------------------
WEIGHTED
AVERAGE WEIGHTED
RANGE OF NUMBER REMAINING AVERAGE NUMBER WEIGHTED
EXERCISE OUTSTANDING CONTRACTUAL EXERCISE EXERCISABLE AT AVERAGE
PRICES AT 12/31/96 LIFE PRICE 12/31/96 EXERCISE PRICE
------ ----------- ---- ----- -------- --------------
<S> <C> <C> <C> <C> <C> <C>
$0.43-$3.00 60,000 5.9 years $1.50 60,000 $1.50
$3.50-$6.20 562,400 8.9 years $4.88 284,255 $4.63
$6.21-$8.50 245,733 10.5 years $6.98 63,166 $7.76
------- -------
868,133 407,421
======= =======
</TABLE>
34
<PAGE> 35
(9) INCOME TAXES
Income tax benefit attributable to loss from operations differed from the
amounts computed by applying the U.S. federal income tax rate of 34 percent as a
result of the following:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 1994
- -------------------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Computed "expected" tax benefit $ 1,989 $ 1,662 $ 1,001
Increase in tax benefit resulting from:
State net operating loss 363 466 126
Loss in foreign subsidiary -- 868 --
Decrease in tax benefit resulting from:
Foreign net loss -- -- (628)
Other (7) (6) 3
Increase in valuation allowance for deferred
tax assets allocated to income tax
expense (2,345) (2,990) (502)
------- ------- -------
$ -- $ -- $ --
======= ======= =======
</TABLE>
The tax effects of temporary differences that give rise to significant portions
of the net deferred tax asset are presented below:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995
- -----------------------------------------------------------------------
(in thousands)
Deferred tax assets:
<S> <C> <C>
Net operating loss carryforwards $ 6,890 $ 3,861
Vacation accrual 135 55
Bad debt reserve 107 92
Other reserves 530 586
------- -------
Gross deferred tax assets 7,662 4,594
Valuation allowance under SFAS 109 (7,600) (4,591)
------- -------
Net deferred tax assets 62 3
Less deferred tax liabilities:
Plant and equipment (62) (3)
------- -------
Net deferred tax $ -- $ --
======= =======
</TABLE>
A valuation allowance in the amount of $7,600,000 and $4,591,000 was established
at December 31, 1996 and 1995, respectively. This allowance has been established
due to the uncertainty in the ability of the Company to benefit from the federal
and state operating loss carryforwards.
35
<PAGE> 36
Subsequently recognized tax benefit relating to the valuation allowance for
deferred tax assets will be allocated as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995
- --------------------------------------------------------------------------------
(in thousands)
<S> <C> <C>
Income tax benefit that would be reported in the
statement of earnings $6,775 $3,823
Charge to goodwill for recognition of acquired tax
assets 825 768
------ ------
$7,600 $4,591
====== ======
</TABLE>
The net operating loss carryforwards ("NOLs") for federal and state tax purposes
at December 31, 1996 are approximately $17,130,000 and $17,008,000, respectively
and expire through 2010 and 2000, respectively.
(10) FOREIGN OPERATIONS
Revenue generated by the Company's UK operations was approximately $448,000 and
$529,000 for fiscal years 1995 and 1994, respectively. No revenue was recorded
in fiscal 1996, since the Company's operations had been discontinued at the end
of 1995. The Company incurred a loss from its UK operations of approximately
$2.1 million and $1.8 million in fiscal 1995 and 1994, respectively. As
discussed in note 1, in order to better utilize its resources on the growth
opportunities in the U.S., the Company discontinued its UK operations in the
fourth quarter 1995 and its assets, consisting primarily of laser equipment,
have been transferred to the U.S.
(11) SUPPLEMENTARY CASH FLOW INFORMATION
The following represents supplementary cash flow information:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31 1996 1995 1994
- -------------------------------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Interest paid $ 223 $ 210 $ 48
======== ======== ========
Non-cash financing activities:
Issuance of Class A Warrants in
conjunction with Bridge Notes $ -- $ -- $ 65
======== ======== ========
Issuance of stock for equipment and other $ -- $ 206 $ --
======== ======== ========
Acquisitions:
Assets acquired $ 10,266 $ 7,697 $ --
Net liabilities assumed (2,533) (3,310) --
Notes payable (1,400) -- --
Common stock issued (1,901) (1,727) --
Common stock issuable (432) -- --
-------- -------- --------
Cash paid 4,000 2,660 --
Less cash acquired (1,146) (296) --
-------- -------- --------
Net cash paid for acquisition $ 2,854 $ 2,364 $ --
======== ======== ========
</TABLE>
36
<PAGE> 37
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
ITEM 10. DIRECTORS AND OFFICERS OF THE REGISTRANT
The response to this item is incorporated by reference from
the discussion responsive thereto under the captions
"Management" and "Compliance with Section 16(a) of the
Securities Exchange Act of 1934" in the Company's Proxy
Statement for the 1996 Annual Meeting of Stockholders.
ITEM 11. EXECUTIVE COMPENSATION
The response to this item is incorporated by reference from
the discussion responsive thereto under the caption "Executive
Compensation" in the Company's Proxy Statement for the 1996
Annual Meeting of Stockholders.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The response to this item is incorporated by reference from
the discussion responsive thereto under the caption "Share
Ownership" in the Company's Proxy Statement for the 1996
Annual Meeting of Stockholders.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
ITEM 14(a)(1). INDEX TO CONSOLIDATED FINANCIAL STATEMENTS COVERED BY REPORT
OF INDEPENDENT AUDITORS
The Consolidated Financial Statements of Sight Resource Corporation are
included in Item 8:
- Independent Auditors' Report
- Consolidated Balance Sheets as of December 31, 1996 and 1995
- Consolidated Statements of Operations for the Years Ended
December 31, 1996, 1995 and 1994
- Consolidated Statements of Stockholders' Equity for the
Years Ended December 31, 1996, 1995 and 1994
- Consolidated Statements of Cash Flows for the Years Ended
December 31, 1996, 1995 and 1994
- Notes to Consolidated Financial Statements
37
<PAGE> 38
ITEM 14(a)(2) INDEX TO CONSOLIDATED FINANCIAL STATEMENT SCHEDULES
Financial statement schedules have not been included because
they are not applicable or the information is included in the
financial statements or notes thereto.
ITEM 14(a)(3) EXHIBITS
The exhibits listed on the Exhibit Index below are filed or
incorporated by reference as part of this report and such
Exhibit Index is hereby incorporated herein by reference.
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
(3.1) - Certificate of Incorporation of the Company (incorporated
herein by reference to Exhibit 3.1 of the Company's
Registration Statement filed with the Securities and Exchange
Commission on Form SB-2 File No. 33-56668)
(3.2) - By-Laws of the Company (incorporated herein by reference to
Exhibit 3.2 of the Company's Registration Statement filed with
the Securities and Exchange Commission on Form SB-2 File No.
33-56668)
(4.1) - Article 4 of the Certificate of Incorporation (incorporated
herein by reference to Exhibit 3.1 of the Company's
Registration Statement filed with the Securities and Exchange
Commission on Form SB-2 File No. 33-56668)
(4.2) - Form of Common Stock Certificate (incorporated herein by
reference to Exhibit 4.2 of the Company's Registration
Statement filed with the Securities and Exchange Commission on
Form SB-2 File No. 33-56668)
(4.3) - Warrant Agreement dated August 24, 1994 between the Registrant
and American Stock Transfer and Trust Company (incorporated
herein by reference to Exhibit 4.5 of the Company's
Registration Statement filed with the Securities and Exchange
Commission on Form S-1 File No. 33-77030)
(4.4) - Form of Redeemable Warrant Certificate (included in 4.3 above)
(4.5) - Form of Class A Warrant (incorporated herein by reference to
the Company's Form 10-K for the year ended December 31, 1994
filed with the Securities and Exchange Commission as Exhibit
4.7)
+(10.1) - Employment Agreement, dated as of December 1, 1992, between
the Registrant and William G. McLendon, as amended
(incorporated by reference herein to Exhibit 10.5 of the
Company's Registration Statement filed with the Securities and
Exchange Commission on Form S-1 File No. 33-77030)
+(10.2) - 1992 Employee, Director and Consultant Stock Option Plan
(incorporated by reference herein to Exhibit 10.7 of the
Company's Registration Statement filed with the Securities and
Exchange Commission on Form S-1 File No. 33-77030)
(10.3) - Letter from Summit Technology, inc. ("Summit") concerning
supply of six laser systems by Summit to the Company
(incorporated herein by reference to Exhibit 10.12 of the
Company's Registration Statement filed with the Securities and
38
<PAGE> 39
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
Exchange Commission on Form SB-2 File No. 33-56668)
** (10.4) - Purchase Agreement between Summit and the Company
(incorporated herein by reference to the Company's Form 10-Q
for the period ending March 31, 1993 filed with the Securities
and Exchange Commission as Exhibit 10.16)
** (10.5) - Joint Venture Agreement relating to the Provision of Vision
Corrective Services in the United Kingdom Using Ophthalmic
Excimer Lasers (incorporated herein by reference to Form 10-Q
for the period ending June 30, 1993 filed with the Securities
and Exchange Commission as Exhibit 10.17)
+(10.6) - Employment Agreement for Stephen M. Blinn, as amended
(incorporated by reference herein to Exhibit 10.18 of the
Company's Registration Statement filed with the Securities and
Exchange Commission on Form S-1 File No. 33-77030)
+(10.7) - Employment Agreement, dated as of February 24, 1995 between
the Registrant and Elliot S. Weinstock, O.D. (incorporated
herein by reference to the Company's Form 10-K for the year
ended December 31, 1994 filed with the Securities and Exchange
Commission as Exhibit 10.9)
** (10.8) - Contract for Professional Services, dated December 21, 1994,
between the Registrant and Massachusetts Eye and Ear
Associates, Inc. (incorporated herein by reference to the
Company's Form 10-K for the year ended December 31, 1994 filed
with the Securities and Exchange Commission as Exhibit 10.10)
** (10.9) - Agreement dated December 21, 1994 between the Registrant and
Massachusetts Eye and Ear Infirmary (incorporated herein by
reference to the Company's Form 10-K for the year ended
December 31, 1994 filed with the Securities and Exchange
Commission as Exhibit 10.11)
(10.10) - Asset Purchase Agreement dated February 24, 1995 between the
Registrant, CEA Acquisition Corporation, Cambridge Eye
Associates, Inc. and Elliot S. Weinstock, O.D. (incorporated
herein by reference to Exhibit 2.1 of the Company's Form 8-K
filed with the Securities and Exchange Commission on March 8,
1995)
(10.11) - Credit Agreement, dated February 20, 1997, between the Company
and Creditanstalt Corporate Finance Corporation, Inc.
(incorporated herein by reference to Exhibit 10.1 of the
Company's Form 8-K filed with the Securities Exchange
Commission on March 7, 1997).
(10.12) - Asset Purchase Agreement dated August 24, 1995 between the
Registrant, Douglas Vision World, Inc., S.J. Haronian,
Kathleen Haronian, Lynn Haronian, Shirley Santoro and
Tri-State Leasing Company (incorporated herein by reference to
Exhibit 2.1 of the Company's Form 8-K filed with the
Securities and Exchange Commission on September 8, 1995)
(10.13) - Asset Transfer and Merger Agreement dated as of July 1,1996 by
and among Sight Resource Corporation, E.B. Acquisition Corp.,
The E.B. Brown Optical Company, Brown Optical Laboratories,
Inc., E.B. Brown Opticians, Inc.,
39
<PAGE> 40
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
Gordon Safran and Evelyn Safran. (Incorporated herein by
reference to Exhibit 2.1 of the Company's Form 8-K filed with
the Securities and Exchange Commission on October 3, 1996.)
(21) - Subsidiaries of the Company; as amended (filed as Exhibit 21)
** - Confidential Treatment has been granted by the Securities and
Exchange Commission.
+ Management contract or compensatory plan, contract or
arrangement.
ITEM 14(b) REPORT ON FORM 8-K
On October 3, 1996, the Company filed a Form 8-K related to
the acquisition of E.B. Brown. In addition, on December 2,
1996, the Company filed a Form 8-KA inclusive of (i) audited
combined balance sheet as of December 31, 1995 and the related
combined statements of income, stockholders' equity and cash
flows for the year then ended, and (ii) unaudited pro forma
consolidated balance sheets as of December 31, 1995 and June
30, 1996 and the related unaudited pro forma consolidated
statements of operations for the year ended December 31, 1995
and the six months ended June 30, 1996.
40
<PAGE> 41
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Amendment No. 1 to
report on Form 10-K to be signed on its behalf by the undersigned, thereunto
duly authorized, in Burlington, Massachusetts on December 29, 1997.
SIGHT RESOURCE CORPORATION
By: /s/ Alan MacDonald
--------------------------------
Alan MacDonald
Vice President, Finance and
Administration (principal financial
and accounting officer)
41
